Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis
- PMID: 3264006
- DOI: 10.1007/BF02918135
Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis
Abstract
The effect of target organ manipulation by means of denervation and treatment with anabolic steroids on the severity of disease in EAMG was assessed in inbred rats. Unilateral limb denervation, a procedure known to increase the AChR content of muscle, 'protected' the denervated leg against antibody-mediated AChr loss in acute EAMG induced by passive transfer of mAb 35 directed against the main immunogenic region. Also in chronic EAMG, brought about by immunizing rats with AChR in complete Freund's adjuvant, the AChR loss of the denervated leg was about one fourth (13.5 vs. 53%) of the control leg. In both acute and chronic EAMG the amount of AChR complexed with antibody was lower in the denervated leg. This lower AChR occupancy with antibody in the denervated leg occurred also in conditions of marked antibody excess and was therefore due to enhanced AChR synthesis. Next the effect of treatment with a weakly virilizing anabolic steroid nandrolone in chronic and acute EAMG was examined in order to examine whether a hypothesized enhanced synthesis of AChR would protect animals from disease. In the absence of an immunosuppressive effect, in terms of concentration of antibodies to AChR, nandrolone treatment protected the rats from severe disease in the chronic EAMG model as shown by the fact that of the 9 rats 6 showed mild (1+) disease and 3 no disease at all; conversely 6 out of 9 control rats showed severe (3+) disease. Rats treated with nandrolone showed a 48 +/- 1.7% loss of AChR compared to a loss of 58 +/- 3.6% in the control rats, suggesting enhanced AChR synthesis. When nandrolone-pretreated rats were given acute EAMG by passive transfer of mAb 35 a paradoxical effect was seen. In contrast to the controls all of the rats pretreated with nandrolone showed severe signs of EAMG; this was associated with a higher loss of AChR and increased consumption of complement C4 as suggested by decreased concentrations of C4 in the serum. Results show increased AChR synthesis to protect against chronic EAMG both in terms of clinical disease (nandrolone) as well as AChR loss (nandrolone, denervation). In addition it was shown that nandrolone increases serum C4 consumption which in the complement-dependent acute EAMG model causes enhancement of the severity of clinical disease and increased AChR loss.
Similar articles
-
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.J Exp Med. 1976 Sep 1;144(3):739-53. doi: 10.1084/jem.144.3.739. J Exp Med. 1976. PMID: 182897 Free PMC article.
-
Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.J Immunol. 1996 Jul 1;157(1):386-92. J Immunol. 1996. PMID: 8683141
-
Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.J Exp Med. 1976 Sep 1;144(3):726-38. doi: 10.1084/jem.144.3.726. J Exp Med. 1976. PMID: 182896 Free PMC article.
-
AChR-specific immunosuppressive therapy of myasthenia gravis.Biochem Pharmacol. 2015 Oct 15;97(4):609-619. doi: 10.1016/j.bcp.2015.07.011. Epub 2015 Jul 26. Biochem Pharmacol. 2015. PMID: 26215875 Review.
-
Animal models of myasthenia gravis.Clin Immunol. 2000 Feb;94(2):75-87. doi: 10.1006/clim.1999.4807. Clin Immunol. 2000. PMID: 10637092 Review.
Cited by
-
Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.Exp Neurol. 2015 Aug;270:18-28. doi: 10.1016/j.expneurol.2015.03.010. Epub 2015 Mar 18. Exp Neurol. 2015. PMID: 25796590 Free PMC article.
-
Autoimmune synaptopathies.Nat Rev Neurosci. 2016 Feb;17(2):103-17. doi: 10.1038/nrn.2015.27. Nat Rev Neurosci. 2016. PMID: 26806629 Review.
-
Myasthenia gravis as a prototype autoimmune receptor disease.Immunol Res. 1997;16(4):341-54. doi: 10.1007/BF02786398. Immunol Res. 1997. PMID: 9439759 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous